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A Protective Effect of Glutathione-S-Transferase
GSTP1*Val105 against Polymorphic Light Eruption
Thomas P. Millard1, Anthony A. Fryer2 and Jane M. McGregor3
Polymorphic light eruption (PLE) is a common skin disease, susceptibility to which is genetically determined.
The prevalence of PLE is significantly increased in patients with lupus erythematosus (LE) including subacute
cutaneous lupus erythematosus (SCLE) and discoid lupus erythematosus (DLE), which may reflect a common
genetic background. Experimental evidence supports a role for reactive oxygen species (ROS) in the
pathogenesis of PLE, and the family of glutathione-S-transferase (GST) enzymes exerts a critical physiological
role in cellular protection against this oxidative damage. Our aim was to look for association between the
functional GST gene polymorphisms and PLE, SCLE, and DLE in a case–control study. The carrier frequency of
GSTP1 Val105 in subjects with PLE was 40%, significantly lower than the carrier frequency in controls (54%,
P¼ 0.019), although significance was lost on correction for multiple testing. However, the carrier frequency of
the GSTP1 Val105 allele in combined cutaneous LE (SCLE and DLE) patients with PLE was 42%, significantly lower
than in those without PLE (72%), which did survive correction (corrected P¼ 0.043). We have identified evidence
supporting a protective GSTP1 allele, the first genetic association to be reported for PLE. This supports a role for
ROS in the pathogenesis of PLE and may provide a therapeutic target for future treatment of this common, often
disabling, condition.
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INTRODUCTION
Polymorphic light eruption (PLE) is one of the most prevalent
skin diseases affecting around 15% of healthy people in
southern England (Pao et al., 1994). It is diagnosed by a
history of transient, non-scarring pruritic papules or vesicles,
typically developing hours, or sometimes days, after sun
exposure and resolving fully over several days. In many
people it is mild, perhaps occurring only on summer
holidays, but it can occasionally be incapacitating, requiring
stringent sunlight avoidance and sometimes treatment with
systemic steroids.
We have recently shown that susceptibility to PLE is
genetically determined, with an estimated heritable compo-
nent of 84% (Millard et al., 2000a). Segregation analysis
indicates a likely polygenic mode of inheritance (McGregor
et al., 2000); however, to date, no susceptibility loci have
been identified for PLE. The prevalence of PLE is significantly
increased in patients with lupus erythematosus (LE), including
subacute cutaneous lupus erythematosus (SCLE) and discoid
lupus erythematosus (DLE) (Nyberg et al., 1997), as well as in
their first-degree relatives (Millard et al., 2001a), which may
reflect a common genetic background. Although little is
known of the etiology of cutaneous LE, available evidence
suggests that this too is likely to have a complex genetic basis
(Millard and McGregor, 2001).
In a recent randomized, controlled photoprovocation
study, the application of topical antioxidants (a-glycosylrutin,
ferulic acid, and tocopheryl acetate) significantly reduced the
severity of the provoked PLE, suggesting a role for reactive
oxygen species (ROS) in its pathogenesis (Hadshiew et al.,
1997). The family of glutathione-S-transferase (GST) enzymes
exerts a critical physiological role in cellular protection
against this oxidative damage (Hayes and Strange, 2000). A
number of common and functional polymorphisms at the four
major GST loci have been described, including null alleles
for GSTM1 and GSTT1, a three-base deletion in GSTM3
intron 6, and a single-nucleotide polymorphism in GSTP1
exon 5 leading to an amino-acid substitution from Ile to Val at
codon 105 (I105V) (Hayes and Strange, 2000).
Ollier et al. (1996) identified a significantly higher carrier
frequency of the homozygous GSTM1-null status in anti-Ro
(SSA)-positive, anti-La (SSB)-negative systemic LE (SLE)
patients than in healthy controls (P¼0.0016). In addition,
the higher frequency of homozygous GSTT1-null status in the
same group of patients approached significance when
compared with controls (P¼0.06). A potential autoimmune
role for these null alleles was suggested, in which the lack of
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GSTM1 and GSTT1 allows ROS to accumulate and
induce apoptosis. Apoptosis causes keratinocytes to express
surface blebs that are rich in autoantigens such as the Ro
antigen, possibly leading to generation of anti-Ro antibody
(Casciola-Rosen and Rosen, 1997).
The objective of this study was to use a case–control
design to look for association between the functional
polymorphisms of the GST gene family and PLE, in addition
to the cutaneous LE phenotypes SCLE (anti-Ro positive) and
DLE (anti-Ro negative).
RESULTS
Demographics
Thirty-six patients with annular SCLE and 49 patients with
DLE were recruited, in addition to 102 healthy first-degree
relatives from the families of 32 LE patients, comprising 87%
of the total number of first-degree relatives in these families.
Twenty-two out of 36 SCLE patients (61%) and 27 out of 49
DLE patients (55%) also described PLE, in addition to 34 out
of 102 first-degree relatives (33%).
GST genotyping of DNA
GST genotyping was undertaken at the GSTM1, M3, T1, and
P1 loci in all patients and relatives. The genotypes of
individuals in all 32 families were consistent with the
presumed family relationships. Nine hundred and five
unrelated controls were typed for GSTM1, 479 for GSTM3,
881 for GSTT1, and 392 for GSTP1, with all genotype
frequencies listed in Table 1.
Association analysis
The GSTP1 locus. The carrier frequency of GSTP1 Val105 in
subjects with PLE (comprising lupus patients with PLE and
their relatives with PLE) was 40%, significantly lower than the
carrier frequency in controls (54%, P¼ 0.019), with an odds
ratio of 0.56 (95% confidence interval 0.33–0.94). Significance
was lost on correction for multiple testing (corrected P¼0.152).
The carrier frequency of GSTP1 Val105 allele in combined
cutaneous LE (SCLE and DLE) patients with PLE was 42%,
significantly lower than in those without PLE (72%, corrected
P¼0.043) with an odds ratio of 0.27 (95% confidence
interval 0.10–0.76). Similarly, the carrier frequency of the
same GSTP1 Val105 allele in relatives with PLE was 36%,
significantly lower than in those without PLE (66%, corrected
P¼0.037), with an odds ratio of 0.29 (95% confidence
interval 0.11–0.76). Cases and controls were in Hardy–Weinberg
equilibrium.
The GSTT1 locus. The frequency of homozygosity for the
GSTT1-null allele in SCLE patients was 30%, significantly
higher than in DLE patients (9%, P¼0.012), but not
significantly higher than in controls (18%, P¼0.080). No
correction of the P-value was necessary because of the
previously reported association of GSTT1-null status with
anti-Ro in LE (Ollier et al., 1996).
The GSTM3 locus. The carrier frequency of the GSTM3*B
allele in SCLE patients was 39%, higher than in DLE patients
(16%); however, significance was lost on correction for
multiple testing (corrected P¼ 0.152).
The GSTM1 locus. Homozygosity for GSTM1-null was
detected in 538 of 905 controls (59%). There were no
significant differences in the frequency of homozygous
GSTM1-null status between SCLE and DLE, or between
patients and relatives with and without PLE.
Table 1. Genotype frequencies of the four GST loci examined
SCLE DLE
Combined
LE with PLE
Combined LE
without PLE
Relatives
with PLE
Relatives
without PLE Controls
GSTM1 null 15 (42%) 28 (57%) 22 (45%) 21 (58%) 17 (50%) 25 (37%) 538 (59%)
GSTM1 positive 21 (58%) 21 (43%) 27 (55%) 15 (42%) 17 (50%) 43 (63%) 367 (41%)
36 49 49 36 34 68 905
GSTM3 AA 22 (61%) 41 (84%) 36 (73%) 27 (75%) 24 (71%) 52 (78%) 359 (75%)
GSTM3 AB 13 (36%) 7 (14%) 12 (24%) 8 (22%) 10 (29%) 14 (21%) 99 (21%)
GSTM3 BB 1 (3%) 1 (2%) 1 (2%) 1 (3%) 0 (0%) 1 (1%) 21 (4%)
36 49 49 36 34 67 479
GSTT1 null 10 (30%) 4 (9%) 7 (15%) 7 (21%) 3 (10%) 14 (23%) 158 (18%)
GSTT1 A 23 (70%) 43 (91%) 39 (85%) 27 (79%) 26 (90%) 48 (77%) 723 (82%)
33 47 46 34 29 62 881
GSTP1 Ile/Ile 14 (40%) 24 (49%) 28 (58%) 10 (28%) 21 (64%) 23 (34%) 181 (46%)
GSTP1 Ile/Val 19 (54%) 21 (43%) 17 (35%) 23 (64%) 9 (27%) 37 (54%) 159 (41%)
GSTP1 Val/Val 2 (6%) 4 (8%) 3 (6%) 3 (8%) 3 (9%) 8 (12%) 52 (13%)
35 49 48 36 33 68 392
DLE, discoid lupus erythematosus; GST, glutathione-S-transferase; LE, lupus erythematosus; PLE, polymorphic light eruption; SCLE, subacute cutaneous
lupus erythematosus.
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Testing of GSTT1 null and HLA DRB1*0301 as independent
variables
The HLA DRB1*0301 extended haplotype was
strongly associated with SCLE in our previous study (Millard
et al., 2001b) so we examined independent assortment of
HLA DRB1*0301 and homozygous GSTT1-null status by
testing the presence and absence of the two factors together
in a 2 by 2 w2-table for SCLE patients (data not shown). This
generated a P-value of 0.400, suggesting that DRB1*0301
and GSTT1 null are truly independent susceptibility factors
for SCLE.
DISCUSSION
These data indicate a possible protective effect of GSTP1
Val105 against PLE and support a role for oxidative stress in
the evolution of PLE. The association is of similar magnitude
in each group and is seen when the groups are combined and
tested against controls. We also extend previous findings of a
positive association between the GSTT1-null genotype and
Ro. Together, these data indicate an important functional role
of ROS and the GST family of enzymes in photosensitivity.
We hypothesize that the individual ability to detoxify ROS
and their products, determined in part by the functional
polymorphism in GSTP1, may contribute to the pathogenesis
of PLE. The GSTP1 enzyme is abundantly expressed in human
skin by keratinocytes and fibroblasts (Konohana et al., 1990).
Encoded at 11q13 (Board et al., 1989), a polymorphism in
exon 5 (A to G at nucleotide 313) substitutes Val for Ile at
codon 105 (I105V) (Ali-Osman et al., 1997). Several
association studies have provided evidence that the GSTP1
I105V substitution is functional and clinically relevant.
Homozygosity for GSTP1 Val105 appears to confer a sixfold
lower risk of asthma compared with homozygotes for GSTP1
Ile105 (P¼ 0.003), confirming an anti-inflammatory role for
GSTP1 Val105 (Fryer et al., 2000). In addition, homozygosity
for GSTP1 Val105 was less common in subjects with positive
skin prick tests to seven common allergens than in those with
negative tests (P¼0.010). Finally, Marshall et al. (2000)
reported association between the GSTP1*C allele (containing
Val at positions 105 and 114) and cutaneous squamous cell
carcinoma after renal transplantation (P¼0.01).
In addition to association studies, strong evidence also
exists that the GSTP1 I105V polymorphism is functional at
the molecular level. GSTP1 enzymes with Val105 have a
sevenfold greater catalytic efficiency for conjugation of GSH
with carcinogenic polycyclic aromatic hydrocarbon diol
epoxides, but a threefold lower catalytic efficiency for the
model GST substrate 1-chloro-2,4-dinitrobenzene (Hu et al.,
1997; Sundberg et al., 1998; Watson et al., 1998). Ali-Osman
et al. (1997) reported that the I105V amino acid is located
within the active site of the GSTP1 peptide. Computer
modeling of the deduced crystal structure illustrated that the
I105V substitution caused significant shifts in the side chains
of several active-site amino-acid residues, possibly allowing
bulky residues to fit better into the space lined by Ile105.
Ali-Osman et al. also suggested that the GSTP1 I105V
substitution could result in subtle alterations in the a-helical
structure of GSTP1, thereby affecting substrate-binding
affinities and catalytic activities of the GSTP1 variants, and
possibly explaining why the activity of GSTP1 containing
Ile105 was lost faster when heated at 45 1C than GSTP1
containing Val105.
Other possible explanations for the apparent protective
effect of GSTP1 Val105 include confounding factors such as
age and sex. Age is unlikely to be a confounding influence
because PLE affects patients of all ages, childhood onward.
Similarly, sex cannot be a significant confounder because
almost all (95%) lupus patients in this study are female, and
the most significant results were found when comparing the
presence of GSTP1 Val105 in lupus patients with and without
PLE. Another potential bias when testing lupus patients
against controls is that patients may be more likely to report
symptoms of PLE than the controls, partly because lupus and
PLE are both photodermatoses. Again, by comparing the
carrier frequencies of GSTP1 Val105 in lupus patients with
and without PLE, we have avoided this potential bias and
demonstrated a significant difference.
GSTT1 is normally encoded at 22q11.2 (Webb et al.,
1996); however, it is frequently deleted with a homozygous
null allele frequency of 18% in our controls. Homozygosity
for null GSTT1 alleles appears to increase the severity of
inflammatory processes mediated by ROS, such as ulcerative
colitis and Crohn’s disease (Duncan et al., 1995). GSTM3,
also expressed in the skin, is encoded at 1p13.3 (Pearson
et al., 1993), with the GSTM3*B allele representing a three-
base deletion at intron 6 of GSTM3, which creates a putative
recognition motif for the negative transcription factor, YY1
(Inskip et al., 1995). GSTM3 alleles are in linkage disequili-
brium with the nearby GSTM1 alleles, at which null
homozygosity affects around half the population (Board
et al., 1990). Ollier et al. (1996) identified a significantly
higher frequency of homozygous GSTM1-null status in anti-
Ro-positive, anti-La-negative SLE patients than in healthy
controls (P¼0.0016), although this was not reproduced in
our study, possibly reflecting the relatively small sample
sizes in each study. The higher frequency of homozygous
GSTT1 null in Ollier’s patients approached significance
when compared with controls (P¼ 0.06). They suggested
a potential autoimmune role for these null alleles in failing
to regulate the activity of ROS, which are capable of
inducing apoptosis. Apoptotic keratinocytes express a
large number of surface blebs that are rich in autoantigens,
such as the Ro antigen; this process may lead to a breakdown
of tolerance to Ro, or at least expose it to circulating
anti-Ro antibodies. In our study, the significant association of
GSTT1-null homozygosity with anti-Ro-positive SCLE versus
anti-Ro-negative DLE is consistent with this proposed
physiological role for GSTT1 in the prevention of
ROS-induced apoptosis and, consequently, in the prevention
of autoimmunity to Ro.
We have identified evidence supporting a protective
GSTP1 allele, which, to our knowledge, is the first genetic
association to be reported for PLE. This supports a role for
ROS in the pathogenesis of PLE, and may provide a
therapeutic target for future treatment of this common, often
disabling, condition.
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MATERIALS AND METHODS
Subjects and controls
Patients with DLE and annular SCLE were recruited from the Louise
Coote Lupus Unit and the Photobiology Clinic at St Thomas’
Hospital. Diagnosis of cutaneous LE was based on the presence of
characteristic clinical features (Millard et al., 2000b) together with
histological and serological investigation. Patients with equivocal
diagnoses were excluded, as were patients with systemic LE. For
inclusion, we stipulated that patients with SCLE must be seropositive
for the anti-Ro (SSA) antibody (Sontheimer et al., 1982) detected by
counterimmunoelectrophoresis (Parodi et al., 1998). The controls
are hospital patients with a range of unrelated, non-inflammatory
diseases including tension headaches, hernias, and varicose veins.
With appropriate ethical approval (and in accordance with the
Declaration of Helsinki Principles), all study patients and first-degree
relatives gave consent, were interviewed, and completed a detailed
questionnaire designed to elicit symptoms of abnormal photosensi-
tivity suggestive of PLE (Millard et al., 2001a); they also provided a
16ml blood sample for DNA extraction. GST genotyping results
from local unrelated healthy individuals were used as controls.
Subjects and controls were white Caucasians.
Identification of GST genotypes
Genomic DNA was extracted from EDTA-anti-coagulated peripheral
blood by a conventional salting-out procedure (Miller et al., 1988).
The DNA was stored at 20 1C until required. All genotyping assays
were performed by workers who were unaware of the clinical status
of individual subjects. PCR assays for identifying GST genotypes
included one DNA sample (selected at random) of known genotype
for each batch of eight samples of unknown genotype, one negative
control (no DNA), and molecular weight markers. About 15% of all
patient DNA samples were reassayed on at least one occasion and
the genotype assignment was confirmed. All genotype assignments
were confirmed by an independent, blinded observer examining the
agarose gels used for separating the assay products.
GSTM1-null genotypes were identified with allele-specific
primers to exon 7 (Yengi et al., 1996; Mattey et al., 1999). GSTT1
(null and expresser) genotypes were also identified with PCR as
described previously. The GSTM3 AA, AB, and BB genotypes were
identified with primers to exons 6 and 7 (Yengi et al., 1996; Mattey
et al., 1999). The Ile105-Val105 substitution in GSTP1 was
examined after PCR amplification using primers to exon 5 (Harries
et al., 1997). The resulting 176-bp fragment was digested with
Alw261 to identify the A–G transition at nucleotide þ 313. PCR
products from homozygotes for the Ile105-encoding allele (GSTP1
Ile105/Ile105 genotype) comprised the undigested 176-bp fragment,
whereas products from homozygous Val105-encoding individuals
(GSTP1 Val105/Val105 genotype) comprised fragments of 91 and
85 bp. PCR products from heterozygotes (GSTP1 Ile105/Val105
genotype) comprised fragments of 176, 91, and 85 bp.
Statistical analysis
The carrier frequency was defined as the proportion of individuals
possessing the specific allele concerned (in heterozygous or
homozygous form) and was compared between phenotypes to
calculate standard 2 by 2 w2-tests. Fisher’s exact test was applied
when an expected cell value was less than 5. The strength of an
association is indicated by the odds ratio. A correction factor was
applied, where an apparent association had not been previously
described, by multiplying the P-value by the number of alleles
tested. Hardy–Weinberg equilibrium was assessed using Stata
(version 8; Stata Corporation, College Station, TX).
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